Belite Bio (BLTE) Projected to Post Quarterly Earnings on Friday

Key Points

• Belite Bio (BLTE) is set to announce its Q2 2025 earnings on August 8th, with analysts expecting a loss of ($0.42) per share.
• Currently, Belite Bio has a market capitalization of $2.07 billion and is trading at a price of $65.01 per share.
• Analyst ratings for the stock vary, with an average rating of "Moderate Buy" and a consensus price target of $96.67.

Belite Bio (NASDAQ:BLTE - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Belite Bio to post earnings of ($0.42) per share for the quarter.

Belite Bio Stock Up 0.3%

Shares of NASDAQ BLTE traded up $0.21 during mid-day trading on Monday, reaching $65.93. 4,480 shares of the company were exchanged, compared to its average volume of 42,602. The company's 50-day simple moving average is $61.59 and its 200-day simple moving average is $60.86. The stock has a market capitalization of $2.10 billion, a P/E ratio of -48.47 and a beta of -1.49. Belite Bio has a twelve month low of $43.70 and a twelve month high of $86.53.

Analyst Ratings Changes

A number of research firms have recently weighed in on BLTE. Cantor Fitzgerald reissued an "overweight" rating on shares of Belite Bio in a report on Thursday, May 15th. Wall Street Zen cut Belite Bio from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of Belite Bio in a report on Thursday, July 3rd. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $96.67.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.